T
Tarik Asselah
Researcher at University of Paris
Publications - 198
Citations - 10153
Tarik Asselah is an academic researcher from University of Paris. The author has contributed to research in topics: Hepatitis C & Ribavirin. The author has an hindex of 43, co-authored 160 publications receiving 9049 citations. Previous affiliations of Tarik Asselah include Sorbonne & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Jordan J. Feld,Ira M. Jacobson,Christophe Hézode,Tarik Asselah,Peter Ruane,Norbert Gruener,Armand Abergel,Alessandra Mangia,Ching-Lung Lai,Henry Lik Yuen Chan,Francesco Mazzotta,Christophe Moreno,Eric M. Yoshida,Stephen D. Shafran,William J. Towner,Tram T. Tran,John McNally,Anu Osinusi,Evguenia S. Svarovskaia,Yanni Zhu,Diana M. Brainard,John G. McHutchison,Kosh Agarwal,Stefan Zeuzem +23 more
TL;DR: Once-daily sofosbuvir-velpatasvir for 12 weeks provided high rates of sustained virologic response among both previously treated and untreated patients infected with HCV genotype 1, 2, 4, 5, or 6, including those with compensated cirrhosis.
Journal ArticleDOI
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu,Vlad Ratziu,Stephen A. Harrison,Sven Francque,Pierre Bedossa,Philippe Lehert,Philippe Lehert,Lawrence Serfaty,Manuel Romero-Gómez,Jérôme Boursier,Manal F. Abdelmalek,Steve Caldwell,Joost P.H. Drenth,Quentin M. Anstee,Dean W. Hum,Rémy Hanf,A. Roudot,S. Megnien,Bart Staels,Arun J. Sanyal,Philippe Mathurin,J. Gournay,Eric Nguyen-Khac,V. de Ledinghen,Dominique Larrey,A. Tran,M. Bourliere,M. Maynard-Muet,Tarik Asselah,Jean Henrion,Frederik Nevens,David Cassiman,Albert Geerts,Christophe Moreno,Ulrich Beuers,Peter R. Galle,Ulrich Spengler,Elisabetta Bugianesi,Antonio Craxì,Mario Angelico,Silvia Fargion,M. Voiculescu,Liana Gheorghe,L. Preotescu,Juan Caballería,Raúl J. Andrade,Javier Crespo,J. L. Callera,Aftab Ala,Guruprasad P. Aithal,G. Abouda,Velimir A. Luketic,M. A. Huang,Stuart C. Gordon,Paul J. Pockros,Fred Poordad,N. Shores,M. W. Moehlen,Kiran Bambha,V. Clark,Sanjaya K. Satapathy,S. Parekh,R. K. Reddy,Muhammad Y. Sheikh,Gyongyi Szabo,John M. Vierling,T. Foster,Guillermo E. Umpierrez,C. Chang,Terry Box,J. Gallegos-Orozco +70 more
TL;DR: A post-hoc analysis of data from trial of patients with NASH showed that elafibranor (120 mg/d for 1 year) resolved NASH without fibrosis worsening, based on a modified definition, in the intention-to-treat analysis and in patients with moderate or severe NASH.
Journal ArticleDOI
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Graham R. Foster,Nezam H. Afdhal,Stuart K. Roberts,Norbert Bräu,E.J. Gane,S. Pianko,E.J. Lawitz,Alexander J. Thompson,Mitchell L. Shiffman,Curtis L Cooper,William J. Towner,Brian Conway,Peter Ruane,M. Bourliere,Tarik Asselah,Thomas Berg,S. Zeuzem,William Rosenberg,Kosh Agarwal,Catherine A.M. Stedman,Hongmei Mo,Hadas Dvory-Sobol,Lingling Han,Jing Wang,John McNally,Anu Osinusi,Diana M. Brainard,John G. McHutchison,Francesco Mazzotta,Tram T. Tran,Stuart C. Gordon,Keyur Patel,Nancy Reau,Alessandra Mangia,Mark S. Sulkowski +34 more
TL;DR: Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment withSofosBuvir-ribavirin.
Journal ArticleDOI
Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
Rami Moucari,Rami Moucari,Vincent Mackiewicz,Olivier Lada,Olivier Lada,Marie-Pierre Ripault,Marie-Pierre Ripault,Corinne Castelnau,Corinne Castelnau,Michelle Martinot-Peignoux,Michelle Martinot-Peignoux,Agnes Dauvergne,Tarik Asselah,Tarik Asselah,Nathalie Boyer,Nathalie Boyer,Pierre Bedossa,Dominique Valla,Dominique Valla,Michel Vidaud,Marie-Hélène Nicolas-Chanoine,Patrick Marcellin,Patrick Marcellin +22 more
TL;DR: Serum quantitative HBsAg may be a useful tool to optimize the management of PEG‐IFN therapy in HBeAg‐negative chronic hepatitis B patients and has high predictive values of SVR to PEG-IFN in H beag‐negative CHB patients.
Journal ArticleDOI
Fibrosis and disease progression in hepatitis C
TL;DR: Serum markers for fibrosis are not reliable and need to be improved and validated, and liver biopsy provides the most accurate information on the stage of fibrosis and grade of necroinflammation, both of which have prognostic significance.